Last reviewed · How we verify
Placebo to BF-200 ALA gel
BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells.
BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells. Used for Actinic keratosis (field treatment), Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma).
At a glance
| Generic name | Placebo to BF-200 ALA gel |
|---|---|
| Sponsor | Biofrontera Bioscience GmbH |
| Drug class | Photodynamic therapy agent |
| Target | Protoporphyrin IX (via aminolevulinic acid metabolism) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Oncology |
| Phase | Phase 3 |
Mechanism of action
BF-200 ALA is a topical prodrug that is converted to protoporphyrin IX in target cells. When exposed to red light (635 nm wavelength), protoporphyrin IX generates singlet oxygen and reactive oxygen species that cause selective destruction of dysplastic and malignant cells. This photodynamic therapy approach is used for treatment of actinic keratosis and other skin lesions.
Approved indications
- Actinic keratosis (field treatment)
- Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)
Common side effects
- Erythema
- Edema
- Crusting
- Phototoxic reaction
- Burning/pain at application site
Key clinical trials
- Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) (PHASE3)
- Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy (PHASE3)
- Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to BF-200 ALA gel CI brief — competitive landscape report
- Placebo to BF-200 ALA gel updates RSS · CI watch RSS
- Biofrontera Bioscience GmbH portfolio CI